

Earnings Presentation: Q2 FY24 26th October 2023

SECRITE Quick Heal

Cyber Security Trends





Large Attack Threat Surface: Due to constant technology innovation and digital adoption



Attacks growing in numbers and intensity, one attack every 39 seconds



Geopolitical situation and many other factors fuelling Cybersecurity risks



10.5 Trillion \$ losses by 2025



Cybersecurity Risk Management a mainstream process



Cyber Security product market deeply fragmented



225 Billion \$ (130 Billion \$ in product) by 2025
Cybersecurity Industry



Cyber Security talent gap is a big challenge



Our Purpose: Innovate to "simplify" securing digital experience.



Focus on grassroot research and adoption of new tech



Ease of manageability & operations for the end customers



Getting the Job Done: Staying one step ahead of the threat actors to protect our customers

Our History





This is Us!





Pioneer of cybersecurity startup in India



1st Listed cybersecurity company in India



Market Leader in India



Proud Owners of Seqrite Lab: Largest in the country



Protecting 9 Mn Active Devices



Patents



Prescence in 75+ countries



1000+ Cybersecurity Professionals



Proud Partners

National Institute of Standards and Technology

Collaborators with US body


SECRITE Quick Heal

Founded By the Visionaries



DR. KAILASH KATKAR MANAGING DIRECTOR

A Visionary Founder and Leader, a Born Entrepreneur, and an Exemplary Trailblazer, he has transformed Quick Heal into a beacon of success and innovation in the Cybersecurity industry. His business acumen has consistently driven remarkable financial performance, customer satisfaction, market leadership making Quick Heal & SEQRITE the preferred choice for customers globally.



DR. SANJAY KATKAR JOINT MANAGING DIRECTOR

Dr. Sanjay Katkar: Co-Founder of Quick Heal Technologies Limited, Joint Force, and Technology Powerhouse behind the company's journey. An unmatched Cybertech Mastermind, who is relentlessly shaping the company's global technology strategy and driving core research and development while pursuing product innovation to fortify cyber security.

Led by the Veterans





MR. VISHAL SALVI
CHIEF EXECUTIVE OFFICER

A Prominent Global Leader, and Distinguished Cybersecurity Expert with a remarkable three-decade journey transforming the cybersecurity and information technology for global brands

His recent role was Global Chief Information Security Officer and Business Head of the Cybersecurity Service Line at Infosys Ltd. He was previously associated with reputed organizations: HDFC Bank, Standard Chartered Bank & PWC.



MR. ANKIT MAHESHWARI
CHIEF FINANCIAL OFFICER



DR. SANJAY AGRAWAL
CHIEF PRODUCT OFFICER



MR. K. VENKATESWARAN SENIOR VICE PRESIDENT -ENTERPRISE SALES



MS. ANUPAMA KATKAR
CHIEF OF OPERATIONAL
EXCELLENCE



MR. DEEPAK MISHRA HEAD, RETAIL SALES



MR. ASHISH PRADHAN
CHIEF TECHNOLOGY OFFICER



MR. SUDHANSHU TRIPATHI
VICE PRESIDENT, HEAD MARKETING
& GROWTH



MS. SWAPNA SANGARI VICE PRESIDENT, HUMAN RESOURCES



MR. ASHISH KADAM
DIRECTOR, GOVERNMENT BUSINESS




Business Momentum



Deconstructing Current Business







Consumer Enterprise

Business mix continues to evolve as we pivot gradually to a holistic cybersecurity player protecting the consumers as well as enterprises

SEQRITE: Self Funded Cybersecurity Startup







Industry growing at a CAGR of 11%


Solving The Big Challenge





Average number of tools used by Enterprises


Organizations pursuing Security Vendor Consolidation



India's only full-stack enterprise cybersecurity platform provider, to offer integrated, modular, scalable, sentient and easy-to-deploy & operate solutions

Through Integrated Cybersecurity Solution





SEQRITE: Business Momentum

SECRITE | Quick Heal

Customer Case Studies



Case Studies available @_https://www.segrite.com/resources/cat/case-studies

Channel Partners Onboarded





Inked partnership with Tata Tele Business Services on cybersecurity for Enterprises

Thought Leadership & Branding



ASSOCHAM, Gujarat



SEQRITE CXO Summit, Mumbai



Cocoon 2023, Kochi



Thought Leadership DPDP Act



Empowering CXO, Bangalore




Customer Testimonials

Market Leaders: Indian Consumer Anti Virus Business Quick Heal | SEQRITE



- Over 25 years into existence
- Market leadership with over 30% in the Indian market
- Robust Sales & Distribution network in India











Current Scenario:

- Current penetration of paid AV in the country 20-25%, while the same in developed geos like US is ~50%.
- Headwinds visible in the segment since H2 FY23 which is easing out gradually

Our Approach:

- Focusing towards maintaining our market share
- Drive consumer awareness in the geography in cybersecurity specific domain

Quick Heal v24 Launch

#DigitallySafe



India's Trusted Partner for Cyber Protection

Manageability of all devices through a single platform







Quantification of security and privacy posture and simple and easy guide to improve score



Consumer Awareness Focused Marketing





Financial Performance

SECRITE

Quick Heal

Financial Highlights (Q2 FY24)



Revenue

₹ **78.4** cr **1** Increased 52% QoQ

EBITDA

PAT

₹12.9 cr

Increased 201% QoQ



Diluted EPS

₹2.42

Increased 201% QoQ

Consumer Revenue

Increased 173% QoQ

₹59.0* cr

Increased 115% QoQ

Enterprise Revenue

₹ 28.8* cr

Increased 9% QoQ

^{*} Based on gross revenues before adjusting for sales incentives

Consolidated P&L





PARTICULARS	Q1 FY 24	Q2 FY 24	H1 FY 24
Total Revenue	51.4	78.4	129.8
Direct Cost	1.2	2.4	3.6
Gross Profit	50.2	76.0	126.2
Gross Margin	97.6%	97.0%	97.2%
Research and Development	31.6	33.0	64.6
Sales and Marketing	18.3	20.4	38.8
General Administration	15.4	11.7	27.0
Total Expenditure	65.3	65.0	130.3
EBITDA	(15.1)	11.0	(4.1)
EBITDA %	-29.3%	14.0%	-3.2%
Depreciation	2.9	3.3	6.2
EBIT	(18.0)	7.7	(10.3)
Other Income	4.7	5.7	10.4
Profit Before Tax (PBT)	(13.3)	13.4	0.1
Tax	(0.5)	0.5	0.0
Profit After Tax (PAT)	(12.8)	12.9	0.1
PAT Margin	-24.8%	16.4%	0.1%

Consolidated Balance Sheet



EQUITY AND LIABILITIES	Mar 31, 2023	Sep 30, 2023
Equity		
Equity Share Capital	53.1	53.1
Share application money		
pending allotment	0.0	0.1
Reserves and Surplus	366.6	342.9
Total Shareholder Funds	419.7	396.1
Non-Current Liabilities		
Net employee defined benefit		
liabilities	0.6	0.0
Other Non Current Liabilities	0.5	1.0
Deferred tax liabilities (net)	0.5	0.4
Total Non-Current Liabilities	1.7	1.4
Current Liabilities:		
Trade and Other Payables	48.6	40.6
Other Financial Liabilities	12.7	8.4
Other Current Liabilities	10.0	14.2
Net employee defined benefit		
liabilities	0.6	1.0
Current tax liabilities (Net)	0.0	0.0
Total Current Liabilities	71.9	64.2
Total Equity & Liabilities	493.3	461.6

ASSETS	Mar 31, 2023	Sep 30, 2023
Non-Current Assets:		
Property, plant and equipment	97.6	92.7
Capital work-in-progress	0.2	0.2
Intangible assets	2.8	1.9
Investment Property	24.1	27.6
Non-current financial assets		
Investments in MF, Tax-Free Bonds, Subs & others	21.5	8.4
Other Financial Asset	8.0	0.8
Deferred tax assets (net)	0.0	0.0
Other Non Current assets	23.0	29.7
Total Non-Current Assets	169.8	161.3
Current assets:		
Inventories	4.5	4.3
Investment in Mutual Fund	176.2	163.6
Trade and other receivables	122.7	107.5
Bank Balances & Cash and Cash Equivalents	11.8	13.0
Investment in Fixed Deposit	0.1	0.1
Other Financial Assets	1.5	1.9
Other Current assets	6.8	9.9
Total Current Assets	323.5	300.3
Total Assets	493.3	461.6

Note: Figures are regrouped/reclassified wherever necessary



Crossed the milestone of 50L cumulative lives touched through all the initiatives



Capital Market Data




Stock Market Performance (as on 30th September 2023)



Price Data (as on 30th September 2023)

Face Value	10.00
Market Price	289.15
52 Week H/L	299.70/127.35
Market Cap (INR Mn)	15,350.32
Equity Shares Outstanding (Mn)	53.09
1 Year Avg. Trading Volume ('000)	179.87
1 Year Avg. Net Turnover (Mn)	36.34

Shareholding Pattern (as on 30th September 2023)



Disclaimer



Quick Heal Technologies Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward-looking statements" based on the currently held beliefs and assumptions of the management of Quick Heal Technologies Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results to differ materially from the results, financial condition, performance, or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment, and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties, and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations, or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration therefrom.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness, and reasonableness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal Valorem Advisors

Email: quickheal@valoremadvisors.com

Tel: +91-22-4903 9500

Investor Relations Officer

Mr. Deepak Kumar

Deepak.Kumar01@quickheal.co.in

Company Secretary

Mr. Sarang H Deshpande

cs@quickheal.co.in

+91-20-66813232

CIN No: L72200MH1995PLC091408

www.quickheal.co.in





Thank You



www.quickheal.co.in www.seqrite.com